PMID- 22942231
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20240418
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 2
IP  - 5
DP  - 2012
TI  - Development of an economic model to assess the cost-effectiveness of hawthorn 
      extract as an adjunct treatment for heart failure in Australia.
LID - 10.1136/bmjopen-2012-001094 [doi]
LID - e001094
AB  - OBJECTIVE: An economic model was developed to evaluate the cost-effectiveness of 
      hawthorn extract as an adjunctive treatment for heart failure in Australia. 
      METHODS: A Markov model of chronic heart failure was developed to compare the 
      costs and outcomes of standard treatment and standard treatment with hawthorn 
      extract. Health states were defined by the New York Heart Association (NYHA) 
      classification system and death. For any given cycle, patients could remain in 
      the same NYHA class, experience an improvement or deterioration in NYHA class, be 
      hospitalised or die. Model inputs were derived from the published medical 
      literature, and the output was quality-adjusted life years (QALYs). Probabilistic 
      sensitivity analysis was conducted. The expected value of perfect information 
      (EVPI) and the expected value of partial perfect information (EVPPI) were 
      conducted to establish the value of further research and the ideal target for 
      such research. RESULTS: Hawthorn extract increased costs by $1866.78 and resulted 
      in a gain of 0.02 QALYs. The incremental cost-effectiveness ratio was $85 160.33 
      per QALY. The cost-effectiveness acceptability curve indicated that at a 
      threshold of $40 000 the new treatment had a 0.29 probability of being 
      cost-effective. The average incremental net monetary benefit (NMB) was -$1791.64, 
      the average NMB for the standard treatment was $92 067.49, and for hawthorn 
      extract $90 275.84. Additional research is potentially cost-effective if research 
      is not proposed to cost more than $325 million. Utilities form the most important 
      target parameter group for further research. CONCLUSIONS: Hawthorn extract is not 
      currently considered to be cost-effective in as an adjunctive treatment for heart 
      failure in Australia. Further research in the area of utilities is warranted.
FAU - Ford, Emily
AU  - Ford E
AD  - School of Population Health, University of Queensland, Brisbane, Queensland, 
      Australia.
FAU - Adams, Jon
AU  - Adams J
FAU - Graves, Nicholas
AU  - Graves N
LA  - eng
PT  - Journal Article
DEP - 20120901
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3437431
EDAT- 2012/09/04 06:00
MHDA- 2012/09/04 06:01
PMCR- 2012/09/01
CRDT- 2012/09/04 06:00
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2012/09/04 06:01 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - bmjopen-2012-001094 [pii]
AID - 10.1136/bmjopen-2012-001094 [doi]
PST - epublish
SO  - BMJ Open. 2012 Sep 1;2(5):e001094. doi: 10.1136/bmjopen-2012-001094. Print 2012.